Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Cancer Vaccines

Cancer Vaccines

Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Genomic analysis of BCG unresponsive non-muscle-invasive bladder cancer identifies drivers of sensitivity to intravesical Gemcitabine/Docetaxel.

bioRxiv : the preprint server for biology·2026

Same author

Perioperative Apalutamide in High-Risk Localized Prostate Cancer.

The New England journal of medicine·2026

Same author

Polygenic risk score with KLK3 SNP-SNP interaction pairs for predicting prostate cancer aggressiveness.

Communications medicine·2026

Same author

Contemporary Perioperative Outcomes of Robotic Retroperitoneal Lymph Node Dissection for Testicular Cancer.

Journal of endourology·2026

Same author

Germline polygenic score for prostate cancer aggressiveness.

medRxiv : the preprint server for health sciences·2026

Same author

Testosterone Treatment in Prostate Cancer Survivors With Hypogonadism: A Randomized Clinical Trial.

JAMA internal medicine·2026

Same journal

An Unprecedented Era of Innovation in Non-Muscle-Invasive Bladder Cancer.

The Urologic clinics of North America·2026

Same journal

Hubert Humphrey's Bladder Cancer: If He Could Have Time Traveled, Would that Have Changed the Outcome?

The Urologic clinics of North America·2026

Same journal

Key Clinical Trials Shaping the Future of Superficial High-Risk Bladder Cancer Management.

The Urologic clinics of North America·2026

Same journal

Future Directions: Artificial Intelligence and Digital Tools in Bladder Cancer Care.

The Urologic clinics of North America·2026

Same journal

Economic Considerations in the Management of Superficial Bladder Cancer.

The Urologic clinics of North America·2026

Same journal

Patient-Centered Approaches to Non-Muscle-Invasive Bladder Cancer Care.

The Urologic clinics of North America·2026

See all related articles

Search research articles

Related Experiment Video

Updated: Jan 10, 2026

Microarray-based Identification of Individual HERV Loci Expression: Application to Biomarker Discovery in Prostate Cancer

Microarray-based Identification of Individual HERV Loci Expression: Application to Biomarker Discovery in Prostate Cancer

Published on: November 2, 2013

Gleason Grade Group 1 Prostate Cancer: Arguments for and Against a Cancer Designation.

Christopher P Dall¹, Michelle S Hirsch², Adam S Kibel¹

¹Department of Urology, Brigham and Women's Hospital, 75 Francis Street, Boston, MA 02115, USA.

The Urologic Clinics of North America

|November 20, 2025

Summary

This summary is machine-generated.

Gleason Grade Group 1 prostate cancer, also known as Gleason score 6, has low metastatic potential. This review discusses renaming this indolent disease to avoid overtreatment and improve patient management strategies.

Keywords:

Gleason score 6 Grade group 1 Low-risk prostate cancer Outcomes Overtreatment Risk

More Related Videos

Author Spotlight: Advancing Prostate Cancer Research Through Improved Tissue Sampling and Biobanking

Author Spotlight: Advancing Prostate Cancer Research Through Improved Tissue Sampling and Biobanking

Published on: November 17, 2023

Use of MRI-ultrasound Fusion to Achieve Targeted Prostate Biopsy

Use of MRI-ultrasound Fusion to Achieve Targeted Prostate Biopsy

Published on: April 9, 2019

Related Experiment Videos

Last Updated: Jan 10, 2026

Microarray-based Identification of Individual HERV Loci Expression: Application to Biomarker Discovery in Prostate Cancer

Microarray-based Identification of Individual HERV Loci Expression: Application to Biomarker Discovery in Prostate Cancer

Published on: November 2, 2013

Author Spotlight: Advancing Prostate Cancer Research Through Improved Tissue Sampling and Biobanking

Author Spotlight: Advancing Prostate Cancer Research Through Improved Tissue Sampling and Biobanking

Published on: November 17, 2023

Use of MRI-ultrasound Fusion to Achieve Targeted Prostate Biopsy

Use of MRI-ultrasound Fusion to Achieve Targeted Prostate Biopsy

Published on: April 9, 2019

Area of Science:

Urologic Oncology
Pathology
Cancer Management

Background:

Managing localized prostate cancer requires balancing treatment for aggressive disease with avoiding overtreatment of indolent cases.
Gleason Grade Group 1 (Gleason score 6) prostate adenocarcinoma is a key focus due to its low metastatic potential.
Current discussions involve renaming Gleason score 6 disease to better reflect its indolent nature.

Purpose of the Study:

To explore the historical context of the Gleason grading system.
To detail the histopathologic characteristics of Gleason score 6 disease.
To examine the clinical implications of Gleason score 6 prostate cancer.

Main Methods:

Literature review of the Gleason grading system evolution.
Analysis of histopathologic features defining Gleason score 6.
Review of clinical outcomes and management strategies for Gleason score 6 disease.

Main Results:

The Gleason grading system has evolved, with Gleason score 6 representing well-differentiated adenocarcinoma.
Gleason score 6 disease is characterized by a low risk of metastasis and progression.
Clinical management often involves active surveillance, challenging the 'cancer' designation.

Conclusions:

Gleason score 6 prostate adenocarcinoma exhibits indolent behavior with minimal metastatic risk.
Renaming Gleason score 6 disease is proposed to mitigate overtreatment and improve patient-centered care.
Understanding the histopathology and clinical implications is crucial for appropriate management decisions.